Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and <sup>11</sup>C-Erlotinib PET
Remy B. Verheijen(AstraZeneca (United Kingdom)), Neeltje Steeghs(Peter MacCallum Cancer Centre), N. Harry Hendrikse(Amsterdam UMC Location Vrije Universiteit Amsterdam), Maqsood Yaqub(University of Geneva), Olaf van Tellingen(Dutch Cancer Society), Emilia Sawicki(Royal Women's Hospital), Jos H. Beijnen(The Netherlands Cancer Institute), Adriaan A. Lammertsma(University Medical Center Groningen), Jan H.M. Schellens(Utrecht University), Bastiaan Nuijen(The Netherlands Cancer Institute), Alwin D. R. Huitema(The Netherlands Cancer Institute)
Cited by 30
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884